Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label single-arm study of rVA576 in mild to moderate bullous pemphigoid
2017-002836-18Phase 2Completed
- Sponsor
- Akari Therapeutics
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nomacopan in Bullous Pemphigoid (BP), sponsored by Akari Therapeutics. Primary endpoint: Safety: incidence of grade 3-5 rVA576-related adverse events. Started Jan 2018; status: completed.
02
Drugs
nomacopan
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2017-002836-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002836-18.